Rappta Therapeutics

Rappta Therapeutics is a late preclinical stage biopharmaceutical company developing a first-in-class series of anti-cancer molecular glues. These molecules are designed to reactivate protein phosphatase 2A (PP2A), a critical tumor suppressor enzyme that regulates protein de-phosphorylation and tumor growth. The technology aims to address the hyperphosphorylation of proteins, which is a hallmark of various cancers and other human diseases.